Shift Toward Targeted Drug Delivery Systems and Non-invasive Treatment Options is Poised to Transform the Landscape
Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Acute On Chronic Liver Failure Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.The growing focus on innovative solutions like gene therapies and regenerative medicine technologies offers significant potential for the global acute on chronic liver failure market, introducing new ways to address the root causes of the condition. Additionally, the shift toward targeted drug delivery systems and non-invasive treatment options is poised to transform the treatment landscape, providing more effective and patient-friendly alternatives that could further propel market growth.However, the lack of FDA-approved therapies for acute on chronic liver failure remains a key challenge, limiting the availability of effective treatment options and hindering market expansion. On a positive note, the continuous improvement of healthcare infrastructure in emerging economies presents a considerable opportunity for market growth, as increased access to treatments becomes more widespread.North America is expected to dominate the global acute on chronic liver failure market due to established healthcare systems, high treatment adoption rates, and significant investments in healthcare infrastructure.
Key Market Players and Competition SynopsisThe companies profiled in this report are based on extensive research and insights from primary experts, evaluating company coverage, product portfolios, and market penetration. The leading players in the global acute on chronic liver failure market include pharmaceutical companies making significant advancements in therapies for liver failure. These companies play a crucial role in improving patient outcomes and addressing the growing demand for effective treatments for liver diseases.
How Can This Report Add Value to an Organization?Product/Innovation Strategy: This report provides comprehensive insights into the current treatments and market trends for acute on chronic liver failure, helping organizations identify opportunities for new product development. By focusing on unmet needs, particularly in the areas of antiviral therapies, liver support agents, and organ transplantation, companies can innovate to meet the growing demand for effective ACLF treatments.Competitive Strategy: To maintain a competitive edge in the acute on chronic liver failure market, companies should focus on improving the safety and efficacy of existing treatments, advancing liver transplantation technologies, and exploring strategic partnerships with research institutions and healthcare providers. Expanding market access in emerging markets and investing in public awareness campaigns will also be critical to gaining market share.Demand - Drivers and Limitations
The demand drivers for the global acute on chronic liver failure market are:
Ongoing investment in research and development of new drug classes, including antivirals and immunosuppressants for acute on chronic liver failure, is propelling market growth
The rising prevalence of chronic liver diseases, especially cirrhosis and chronic hepatitis, is contributing to a higher occurrence of acute on chronic liver failure, thereby fuelling the demand for effective treatments
Limitations:
The lack of FDA-approved therapies for acute on chronic liver failure restricts access to effective treatments, impeding market growth
Some of the prominent pharmaceutical companies established in the global acute on chronic liver failure market include:
Grifols Therapeutics LLC
GENFIT Corp
Martin Pharmaceuticals
Key Topics Covered: 1. Global Acute On Chronic Liver Failure Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Acute On Chronic Liver Failure1.2.1 By Region1.3 Market Trends1.4 Clinical Trial Analysis1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Acute On Chronic Liver Failure Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Acute On Chronic Liver Failure Market (by Country)2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Acute On Chronic Liver Failure Market (by Country)2.2.3.1.1 Germany2.2.3.1.2 France2.2.3.1.3 Italy2.2.3.1.4 U.K.2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific Acute On Chronic Liver Failure Market (by Country)2.3.3.1.1 Japan2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Acute On Chronic Liver Failure Market: Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Grifols Therapeutics LLC3.2.1.1 Company Overview3.2.1.2 Product Portfolio3.2.1.3 Target Customers/End Users3.2.1.4 Key Personnels3.2.1.5 Analyst View3.2.2 GENFIT Corp3.2.2.1 Company Overview3.2.2.2 Product Portfolio3.2.2.3 Target Customers / End Users3.2.2.4 Key Personnels3.2.2.5 Analyst View3.2.3 Martin Pharmaceuticals3.2.3.1 Company Overview3.2.3.2 Product Portfolio3.2.3.3 Target Customers / End Users3.2.3.4 Key Personnels3.2.3.5 Analyst View4. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/vywy8p
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Business confidence subdued amid tariffs but 'worst-case' less likely: BoC survey
A pair of reports from the Bank of Canada say tariff-related uncertainty continued to put a damper on business and consumer sentiment in the second quarter, but the worst-case trade scenarios previously anticipated seem less likely. The central bank's business outlook survey said 28 per cent of firms are now planning for a recession in Canada, down from 32 per cent last quarter but still up from 15 per cent over the previous two quarters. Sales outlooks remain pessimistic overall due to widespread concerns about the effects of a slowing economy, but the report says recent monthly surveys suggest some improvement in firms' outlooks, especially among exporters because few have been directly affected by current tariffs. Meanwhile, the Canadian survey of consumer expectations says spending intentions have weakened further because of persistent tariff threats. Consumers also continue to see the labour market as soft amid "elevated" fears of job loss. The reports come ahead of the Bank of Canada's next interest rate decision and monetary policy report set for July 30. This report by The Canadian Press was first published July 21, 2025. Sammy Hudes, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
This Energy Infrastructure Company Boasts Stable Cash Flows and High Payouts
Enbridge Inc. (NYSE:ENB) is included among the 12 Best Oil and Gas Dividend Stocks to Buy Now. A large natural gas pipeline snaking through a rural landscape. As one of the only dividend aristocrats in its sector, Enbridge Inc. (NYSE:ENB) has increased its dividend for 30 consecutive years and expects to continue this momentum by growing its business by 5% per year through the end of the decade. Currently, the company offers a quarterly dividend of C$0.9425 per share and has a dividend yield of 5.96%, as of July 15. Enbridge Inc. (NYSE:ENB) boasts a toll-booth-like pipeline and utility business that centers around fixed fees and other contracts that generate stable cash flows, allowing the company to maintain its dividend growth at a CAGR of 9% over the past three decades. The company is also diversifying beyond pipelines and into renewable energy through solar and wind projects. Moreover, it reported a secured growth backlog of $28 billion at the end of Q1 2025, ensuring sustainable cash flow and dividend growth in the future. Enbridge Inc. (NYSE:ENB) is a midstream energy company that focuses on transporting and distributing oil, natural gas, and natural gas liquids. The Canadian company moves about 30% of the crude oil produced in North America. While we acknowledge the potential of ENB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Nuclear Energy Stocks to Buy Right Now and The 5 Energy Stocks Billionaires are Quietly Piling Into. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
7 credit score myths you should stop believing
If you've ever learned anything about credit scores from a friend, a family member, or social media, I'm sorry to tell you this, but you may have some unlearning to do. In my past role as an NFCC-certified credit counselor and my cumulative 12 years working as a financial educator, I've heard some bizarre myths and rumors about credit scores, a few of which are really popular. Sure, myths can be fun. But when it comes to credit scores, they have major consequences. Some of the most commonly held myths can leave you with perpetually low credit scores and make it hard for you to qualify for mortgages or credit cards. Here are the most common and harmful credit myths I've come across, and the truth you need to know about each one. This embedded content is not available in your region. Top credit score myths debunked 1. Checking your credit reports lowers your scores When I encourage people to pull their credit reports, I tend to hear the same response: "Won't that hurt my credit scores?" The answer is a firm "no!" The truth is, pulling your own credit reports does not hurt your credit scores at all. In fact, if you don't pull and review your reports, you may never be able to build good credit. That's because reviewing your reports helps you with all of the following: Finding out what's in your credit file Discovering what needs to be improved Finding and disputing credit report errors Catching signs of identity theft You can pull your credit reports for free once a week at 2. You need to carry a balance to build good credit I wish I had a dollar for every time someone told me that carrying a 30% credit card balance (that's a balance equal to 30% of your card limit) helps you build good credit scores. The reality is that the lower your credit card balance is, the better for both your credit scores and your wallet. When you have low balances, you reduce your credit utilization ratio (the amount of credit you're using compared to your total available balance). The lower your credit utilization, the better it is for your credit scores because you're showing lenders that you don't need credit cards to cover your expenses. Additionally, if you pay off your full credit card balance by the monthly due date — which I highly recommend — you can avoid high interest charges. 3. I don't need to worry about my credit until I want a loan In my credit counseling days, I often got calls from people who wanted help fixing their credit ASAP. Often, it was because they had just submitted an application for a car loan, or made an offer on a new home. Unfortunately, I had to let them know that it usually takes months, and sometimes years, to clean up credit mistakes and build good credit. For example, even if you pay off your credit card today, it can take a month or more for the $0 balance to show up on your credit reports and be factored into your credit scores. And if you want to build good credit scores, it can take months or even years, depending on the condition your credit is in now. 4. Paying off collection debt helps your credit scores I receive several emails a month from people who are desperate to remove old collection accounts from their credit reports. The reason? They want to improve their credit scores — fast. Unfortunately, there's no guarantee that paying off a collection account will improve your credit scores. Here are a few credit score facts to keep in mind before you consider sending money to a debt collector: Medical collection debt under $500 has no impact on your credit scores. Paying off a collection account does not remove the account from your credit reports. Most credit score calculations do not make a distinction between paid and unpaid collections. That said, depending on the type of debt, you may want to pay off collection accounts anyway. It can stop debt collectors from contacting you or even taking legal action against you. However, if the debt is old and close to falling off your report (typically seven years from the original delinquency), paying may reset the clock on the debt. So, if you're unsure about how to handle a debt in collections, it's a good idea to reach out to an accredited credit counselor for guidance. 5. Disputing accurate information will improve your credit scores Most credit myths are a mix of truth and fiction, and this one is no different. Here's what's true: If you find an error in your credit reports, you have the right to file a dispute (for free) and get the information corrected or removed. But you do not have the right to get accurate information removed from your reports. Unfortunately, some people view the dispute process as an invitation to try and remove any negative information, even if it's accurate. In fact, there are credit repair companies that charge money to dispute correct information on your behalf. If you do dispute correct information, there's a chance it will be removed from your reports while the credit bureau investigates your claim. But once they confirm that it's accurate, the information will reappear on your reports. 6. A good credit score means you're rich Wealth doesn't impact your credit scores, at least not directly. Yes, your income level can impact how much money you borrow, whether you're able to repay loans and credit cards, and other behaviors that affect your credit. However, your income is not a factor in determining your credit scores. In fact, even if you're considered rich, but you don't pay your debt on time, you will have poor credit scores. 7. Bad credit history follows you forever As a credit counselor, I spoke to many people who believed that a bankruptcy or foreclosure from the '80s or '90s was still damaging their credit. While events such as bankruptcy, foreclosure, and repossession will cause severe damage to your credit scores, the damage only follows you for a limited time. Here's a breakdown of the timelines: 7 years: Missed debt payments (at least 30 days late), vehicle repossession, home foreclosure, and Chapter 13 bankruptcy. 10 years: Chapter 7 bankruptcy and positive credit information As negative information gets older, it has less of an impact on your credit scores. Once it's removed, it has no impact at all. Up Next Up Next
